Wistar researchers have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and facilitate tumor cell seeding and...
15-Oct-2018 8:05 AM EDT Add to Favorites
Synthetic DNA Vaccine Against Ebola Virus Shows Potent and Long-term Efficacy in Preclinical Studies
A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.
10-Oct-2018 9:10 AM EDT Add to Favorites
Wistar scientists have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene.
8-Oct-2018 10:05 AM EDT Add to Favorites
Engineered Synthetic DNA-Encoded Checkpoint Inhibitor Antibodies Advance the Field of Cancer Immunotherapy
Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule that blocks anti-cancer...
4-Oct-2018 10:05 AM EDT Add to Favorites
Targeting Multiple Members of a Family of Tumor Antigens with a Synthetic DNA Vaccine Shows Promise for Cancer Immunotherapy
Wistar scientists have implemented a novel structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer.
27-Sep-2018 11:15 AM EDT Add to Favorites
Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers
A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the first...
26-Sep-2018 10:05 AM EDT Add to Favorites
Synthetic DNA Vaccine Effective Against Influenza A Virus Subtype That Is Responsible for More Severe Influenza Seasons
Wistar scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.
6-Sep-2018 1:15 PM EDT Add to Favorites
A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published...
5-Sep-2018 11:40 AM EDT Add to Favorites
see all news
Dr. Luis Montaner, Wistar Institute HIV/AIDS Expert, Can Address His Work in the Search for a Cure, for World AIDS Day
26-Nov-2013 2:25 PM EST
22-Feb-2013 4:15 PM EST
The Winter Sun May Not Be Warm, but Still Can Be Dangerous. Wistar Melanoma Expert on Wintertime UV Risks
22-Jan-2013 2:30 PM ESTsee all experts